Advanced in ZAP70-Related Severe Combined Immunodeficiency

Xuemei M. Tang

12 Middle Urumqi Road, 
Shanghai, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in ZAP70-Related Severe Combined Immunodeficiency
12 Middle Urumqi Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Xuemei Tang practices in Shanghai, China. Tang is rated as an Advanced expert by MediFind in the treatment of ZAP70-Related Severe Combined Immunodeficiency. Their top areas of expertise are X-Linked Lymphoproliferative Disease, Juvenile Idiopathic Arthritis (JIA), Cyclic Neutropenia, Primary Immunodeficiency (PID), and Splenectomy.

Their clinical research consists of co-authoring 146 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of ZAP70-Related Severe Combined Immunodeficiency.

Locations

12 Middle Urumqi Road, Shanghai, 200040, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

146 Total Publications

Breastfeeding duration and the risk of systemic juvenile idiopathic arthritis: a cross-sectional study.
Breastfeeding duration and the risk of systemic juvenile idiopathic arthritis: a cross-sectional study.
Journal: Frontiers in nutrition
Published: June 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tang's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile